BioMarin Pharmaceutical Inc. Cost of Revenue

Cost of Revenue of BMRN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending March 31, 2022 was $133 Million (a -2.05% decrease compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue decreased by -7.01%
  • Annual Cost of Revenue for 2021 was $532 Million (a -9.22% decrease from previous year)
  • Annual Cost of Revenue for 2020 was $586 Million (a 41.89% increase from previous year)
  • Annual Cost of Revenue for 2019 was $413 Million (a 19.36% increase from previous year)
  • Twelve month Cost of Revenue ending March 31, 2022 was $529 Million (a -0.56% decrease compared to previous quarter)
  • Twelve month trailing Cost of Revenue decreased by -10.73% year-over-year
Trailing Cost of Revenue for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$529 Million $532 Million $523 Million $593 Million
Visit stockrow.com/BMRN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of BioMarin Pharmaceutical Inc.

Most recent Cost of Revenueof BMRN including historical data for past 10 years.

Interactive Chart of Cost of Revenue of BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $132.57
2021 $135.34 $118.96 $142.56 $135.57 $532.0
2020 $126.14 $188.79 $97.97 $111.37 $586.0
2019 $95.9 $96.95 $77.44 $89.18 $413.0
2018 $75.02 $78.89 $79.02 $82.33 $346.0
2017 $76.0 $59.48 $56.31 $50.01 $278.0
2016 $64.15 $50.74 $51.62 $43.12 $209.62
2015 $48.04 $34.9 $38.06 $31.0 $152.01
2014 $38.32 $29.92 $31.21 $22.82 $122.27
2013 $17.27 $28.05 $22.57 $20.5 $88.39
2012 $26.53 $24.62 $23.57 $17.11 $91.83
2011 $21.52 $22.45 $19.26 $84.02

Business Profile of BioMarin Pharmaceutical Inc.

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.